AMSPARITY 40 mg, solution for injection in a pre-filled syringe 2 syringes of 0.8 ml
Active ingredients: Adalimumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection2 syringes of 0.8 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- AMSPARITY 40 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 2 seringue(s) préremplie(s) en verre de 0,8 ml avec 2 tampon(s) alcoolisé(s)
- Marketing authorisation holder
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 30 Sept 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62720332CIP73021632CIP133400930216323Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ADALIMUMABsolution | 40 mg · une seringue préremplie 0,8 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.